<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00312052</url>
  </required_header>
  <id_info>
    <org_study_id>E5555-G000-201</org_study_id>
    <secondary_id>2005-006029-94</secondary_id>
    <nct_id>NCT00312052</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to assess the safety and tolerability of E5555 in
      subjects with coronary artery disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a multicenter, randomized, double-blind, placebo-controlled trial of E5555, a PAR-1
      inhibitor. The total duration of individual study participation was 28 weeks (196 days). This
      included a treatment period of 24 weeks (168 days) and a follow-up period of 4 weeks (28
      days).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability - especially the risk of bleeding</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of major adverse cardiovascular events; the effect on platelet aggregation inhibition. Exploratory Outcome Measure: effects on endovascular inflammatory processes</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">720</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>E5555 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received one 50 mg E5555 and two 100 mg placebo tablets, once orally daily for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E5555 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received one 50 mg placebo, one 100 mg E5555 and one 100 mg placebo tablets, once orally daily for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E5555 200 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received one 50 mg placebo and two 100 mg E5555 tablets were taken orally once daily for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received one 50 mg placebo and two 100 mg placebo tablets, once orally daily for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E5555</intervention_name>
    <description>50 mg or 100 mg E5555 tablets</description>
    <arm_group_label>E5555 50 mg</arm_group_label>
    <arm_group_label>E5555 100 mg</arm_group_label>
    <arm_group_label>E5555 200 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>50 mg and/or 100 mg placebo tablets</description>
    <arm_group_label>E5555 50 mg</arm_group_label>
    <arm_group_label>E5555 100 mg</arm_group_label>
    <arm_group_label>E5555 200 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          1. Males or Females, 45 - 80 years of age

          2. Confirmed coronary artery disease defined as one of the following:

               -  Post-acute coronary syndrome or myocardial infarction or

               -  Post percutaneous coronary intervention or coronary artery bypass graft or
                  oAngina pectoris with documented (electrocardiogram or imaging study) ischemia or

               -  Angiographically documented lesion occluding â‰¥70% of a coronary vessel

             And at high risk as defined as one or more of the following:

               -  Elevated hsCRP (high-sensitivity C-reactive protein)

               -  Diabetes mellitus

               -  History of carotid artery disease and/or peripheral artery disease

               -  Thrombo-embolic transient ischemic attack or stroke &gt;1 year prior to screening

          3. All subjects must be receiving low dose aspirin and/or clopidogrel and/or ticlopidine.

        EXCLUSION CRITERIA

          1. History of acquired or congenital bleeding disorder, coagulopathy or platelet
             disorder, or history of pathological bleeding within the last 6 months

          2. History of intracranial bleeding, history of hemorrhagic retinopathy or known
             structural cerebral vascular lesion

          3. Clinically significant hematological, hepatic or renal abnormalities

          4. Patients with some specific ST-segment changes, severe congestive heart failure or
             uncontrolled cardiac arrhythmias at baseline

          5. Recent significant (as determined by the investigator) cardiovascular events
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Riefler, MD</last_name>
    <role>Study Director</role>
    <affiliation>Eisai Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Florida Research Network</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Lakes Heart Center of Alpena</name>
      <address>
        <city>Alpena</city>
        <state>Michigan</state>
        <zip>49707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2006</study_first_submitted>
  <study_first_submitted_qc>April 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2006</study_first_posted>
  <disposition_first_submitted>May 21, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>May 21, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 29, 2013</disposition_first_posted>
  <last_update_submitted>December 1, 2016</last_update_submitted>
  <last_update_submitted_qc>December 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

